Home  |  Contact Us  |  About Cerus  |  Site Map  |  Search:

INTERCEPT Blood System for Platelets -
Pathogen Inactivation Data: Leukocytes

The INTERCEPT Blood System for platelets has been shown to inactivate contaminating donor leukocytes including T-cells in platelet products. Various in vitro studies have demonstrated inhibition of leukocyte replication as well as inhibition of cytokine synthesis by leukocytes following photochemical treatment. The results of these studies are summarized below:

Assay System
Extent of Inactivation
Platelets in
plasma/additive solution
Platelets in
plasma
In vitro Limiting dilution assay
>5.4 log10 reduction of
viable T-cells
≥6.1 log10 reduction of viable T-cells

DNA modification
Approximately one amotosalen adduct
per 83 base pairs
Approximately one amotosalen adduct per 89 base pairs
Polymerase chain reaction
Amplification inhibited by amotosalen – DNA adducts
-
Cytokine synthesis
Elimination of IL-8, IL-1β synthesis during storage
-
In vivo

Murine transfusion model
Prevention of TA-GVHD in a murine parent to F1 transfusion model
-

“-” means not tested

Previous PagePlatelet Technical Data Sheet Page 6 of 7Next Page
© Cerus Corporation. All Rights Reserved.

Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma. No pathogen inactivation system has been shown to inactivate all pathogens.

Website design by NetPilot Web Solutions
Legal Info  |   Privacy Policy